Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
about
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectinSelective down-regulation of tyrosinase family gene TYRP1 by inhibition of the activity of melanocyte transcription factor, MITFT-cell clonotypes in cancerNew perspectives on the role of vitiligo in immune responses to melanomaEvidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidityImmunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta.Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunitySelf-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapyAntigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy.Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.Dissecting the immune response to moloney murine sarcoma/leukemia virus-induced tumors by means of a DNA vaccination approach.Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor controlHuman tumor antigens for cancer vaccine development.Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity.Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responsesDefined synthetic vaccines.Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen.Optimal epitope composition after antigen screening using a live bacterial delivery vector: application to TRP-2.Interferon γ limits the effectiveness of melanoma peptide vaccines.Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.An Aggressive Hypoxia Related Subpopulation of Melanoma Cells is TRP-2 Negative.Mouse model for pre-clinical study of human cancer immunotherapy.DNA vaccines encoding Ii-PADRE generates potent PADRE-specific CD4+ T-cell immune responses and enhances vaccine potencyTherapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMaxVaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific antitumor immunity from T-cell populations undergoing homeostatic peripheral expansion after BMT.Developing recombinant and synthetic vaccines for the treatment of melanoma.Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.Inducing autoimmune disease to treat cancer.Maximizing CD8+ T cell responses elicited by peptide vaccines containing CpG oligodeoxynucleotides.A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine modelTumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.Mutated mitogen-activated protein kinase: a tumor rejection antigen of mouse sarcomaActivation of preexisting T cell clones by targeted interleukin 2 therapy.
P2860
Q24315864-20359C55-4091-4D0C-B949-5F1F9DF551E4Q24540321-EB525683-1DB4-49E7-9852-A73723E2141FQ24803891-E818AEE7-E98E-494A-AAD5-1BD78DAB6AE4Q26996799-A30A3EF0-18F5-4AB2-8139-AF0BC460656BQ28360452-D17DDC67-E83F-4060-8985-BC75E1F7AF92Q28363065-B1CECBF8-FD02-44EA-9532-B1B973B181DDQ28749317-23EE34A1-6658-436F-9587-4E238C1C5524Q30305530-F5F2F263-34A0-4437-BF91-92D9C1207857Q30310231-F2EE5399-3822-489A-8540-535C09AE8120Q31023643-D1860DF5-62F9-40F7-8D61-441935B442FEQ33633839-A1ED13DC-1788-41E2-9822-D0AADDF3D376Q33653487-EAA1062A-C00B-4BB5-8BFD-205337AF146EQ33713083-1C98DFA0-4754-4C3D-9897-085F690C8CC1Q33724224-2F05F2CC-FDBA-4489-9F74-70DA9CE9AE9CQ33776127-FB4BC4CA-E51A-48CD-A979-D7C4D0B8B52BQ33817957-0D6C1CB2-D28A-4310-B4EA-F141F616F9F3Q33930126-CC9D3A75-13E4-4AA6-B646-F37E19230FE3Q34280941-6329A940-C0E5-4050-A8F0-968CCD9DDF43Q34509094-AB99FBBA-BFC0-4B64-91D2-92F2EC07B519Q34558230-864A2767-8A0E-4B3C-A955-97E43C5B186BQ34568835-4CF9BD95-E55F-4D5B-95F8-5FA65D902503Q34677842-19F88F96-D11D-4003-B060-F8495A588057Q34789146-E4217C0F-A6B4-465A-9CB7-3BA5DC6B4543Q34792069-5C1BFBCB-3839-44B9-B82B-ECB54ECCB762Q35049933-A42E3E66-1919-4FED-AA26-71F386564841Q35064131-03ED8550-CCCC-499B-AB93-87F38B9AD030Q35152524-DC3D9BBC-425C-4DAC-B267-078015D89C98Q35181705-E4B758DF-0A45-4FE1-B2AB-4064AE45F973Q35210348-7DE8A5C5-5553-4130-9F42-5AD7C78E0340Q35790603-A49E0C9D-F202-447A-B0A1-48EDC8B8D05FQ35850723-3952E15C-E8E1-4736-8D9D-51518E65BB83Q35946196-F822E0C9-FC72-4CA0-85E6-137DC4782CE6Q35954142-2567700A-5C63-447F-9F58-ACDC15C76BDDQ35976297-0C6D8517-CE0D-497D-9722-416240B8516FQ36015394-43D88488-8F77-410F-87CC-661C3B6B8020Q36037271-9E1AECE1-0CF2-42E5-839D-7F8655C2C8C4Q36167792-C041B8EC-C8B3-40EB-B2DD-D32183021B1DQ36177023-9AF6D87E-29A8-4E09-B381-B58FB4D767D8Q36184608-7B260CF6-62D6-454A-BDAB-BAD8765B874BQ36219989-8D6BE237-9E4A-4579-98EE-9D5C59F5BE60
P2860
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Identification of tyrosinase-r ...... antigen for the B16 melanoma.
@ast
Identification of tyrosinase-r ...... antigen for the B16 melanoma.
@en
type
label
Identification of tyrosinase-r ...... antigen for the B16 melanoma.
@ast
Identification of tyrosinase-r ...... antigen for the B16 melanoma.
@en
prefLabel
Identification of tyrosinase-r ...... antigen for the B16 melanoma.
@ast
Identification of tyrosinase-r ...... antigen for the B16 melanoma.
@en
P2093
P2860
P356
P1476
Identification of tyrosinase-r ...... antigen for the B16 melanoma.
@en
P2093
Perry-Lalley D
Robbins PF
Rosenberg SA
el-Gamil M
P2860
P304
P356
10.1084/JEM.185.3.453
P407
P577
1997-02-01T00:00:00Z